Shire PLC has acquired privately held Foresight Biotherapeutics for $300m, gaining FST-100, a Phase III-ready drug in development for infectious conjunctivitis and a commercial complement to Shire's lifitegrast pending at FDA.
Shire already has plans to expand the Phase III development of FST-100 beyond viral conjunctivitis to include the bacterial form...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?